Chemistry:Glesatinib
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Routes of administration | By mouth |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C31H27F2N5O3S2 |
| Molar mass | 619.71 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Glesatinib (MGCD265) is an experimental anti-cancer drug.[1][2]
It is in phase 2 clinical trials for non-small cell lung cancer (NSCLC).[3]
It is a spectrum selective tyrosine[1] kinase inhibitor "for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET".[4]
See also
- Mirati Therapeutics
References
- ↑ 1.0 1.1 "Glesatinib". National Cancer Institute at the National Institutes of Health. U.S. Department of Health and Human Services. https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=597305.
- ↑ "Glesatinib, a c-MET/SMO Dual Inhibitor, Antagonizes P-glycoprotein Mediated Multidrug Resistance in Cancer Cells". Frontiers in Oncology 9: 313. 2019. doi:10.3389/fonc.2019.00313. PMID 31106148.
- ↑ Clinical trial number NCT02954991 for "Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer " at ClinicalTrials.gov
- ↑ "Mirati Therapeutics Provides Update On Glesatinib And Sitravatinib Clinical Trials And Pipeline Programs". PipelineReview.com. January 2017. http://pipelinereview.com/index.php/2017010663534/Small-Molecules/Mirati-Therapeutics-Provides-Update-On-Glesatinib-And-Sitravatinib-Clinical-Trials-And-Pipeline-Programs.html.
External links
 |  |
